ClinicalTrials.gg
CompletedNCT05327231Updated Nov 16, 2022

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

A Phase 1 interventional study of IN10018 and Docetaxel in Gastric Cancer, sponsored by InxMed (Shanghai) Co., Ltd.. Completed at 8 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-16.

Sponsored by InxMed (Shanghai) Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Jul 2020, registered Mar 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,184 studies in Stomach Neoplasms with a site in China — 481 open to participants now, 557 under way, 50 of them phase 3. Stomach Neoplasms · China.

Enrollment
714th of 881
33 · median 87
Started
2020
with 66 others
Phase 1
93 of 1,184
48 open now
Registered
603rd of 1,184
by date

Among the 1,184 studies in Stomach Neoplasms with a site in China, this one is the 714th largest by enrollment of the 881 interventional ones that give a count, is one of 67 that started in 2020, is one of 93 in phase 1, and was the 603rd registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

481 of the 1,184 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

476 more — sign in →

All 481 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,184 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a phase I, multi-center clinical trial to evaluate the safety, tolerability, antitumor activities and pharmacokinetics of IN10018 as monotherapy or in combination with docetaxel in previously-treated locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Read the detailed description

Eligibility patients will be enrolled into the study and assigned to treatment groups: 1) IN10018 monotherapy group, and 2) IN10018+Docetaxel combination group. This study contains 2 parts of dose escalation and dose expansion for each treatment group. The monotherapy group will enroll patients failed to respond to standard therapy or standard or curative therapy does not exist or is not tolerable, and explore IN10018 monotherapy RP2D with the starting dose of IN10018 100mg QD per 3+3 design. The combination group will enroll patients who have disease progression within 3 months after at least first-line therapy, and explore IN10018+docetaxel RP2D with the starting dose of IN10018 100mg QD + docetaxel 75mg/m2 per 3+3 design. The dose expansion part will start after attaining the RP2D of IN10018 monotherapy and IN10018+docetaxel combination therapy.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Has or cytologically confirmed diagnosis of locally advanced and/or gastric or GEJ adenocarcinoma.

    • For monotherapy, participants need to be failed to respond to standard therapy or standard or curative therapy does not exist or is not tolerable.
    • For combination therapy, participants need to have disease progression within 3 months after at least therapy.
  • 2.Has at least one measurable tumor lesion per 1.1.
  • 3.Has an performance status of 0 or 1.
  • 4.Estimated is more than 3 months.
  • 5.Adequate organ and bone marrow functions.
  • 6.Has been fully informed and provided written for the study

Exclusion criteria

Exclusion Criteria:

  • 1.Has other histological types other than adenocarcinoma.
  • 2.For participants with /neu positive tumors or have an unknown tumor status, need to match the following:

    • If HER2/neu positive, participant must have documentation of disease progression on trastuzumab or other anti-HER2/neu therapy.
    • Participants with unknown status must have their HER2/neu status determined locally. If HER2/neu-negative, the participant will be eligible. If HER2/neu-positive, the participant must have documentation of disease progression on trastuzumab or other anti-HER2/neu therapy.
  • 3.Has had disease progression after docetaxel/paclitaxel containing treatment (combination therapy only).
  • 4.Has received prior systemic therapies (i.e. chemotherapy, biotherapy, endocrinotherapy, and immunotherapy) within 4 weeks prior to start of study treatment.
  • 5.Has received prior radiotherapy within 2 weeks prior to start of study treatment.
  • 6.Has severe allergy or to IN10018 and/or docetaxel, or any components used in their preparation or has for taxane therapy. For participants in monotherapy group, only restriction to IN10018 applies.
  • 7.Has severe renal disease or impaired renal function.
  • 8.Has an active infection requiring systemic therapy within 2 weeks prior to start of study treatment.
  • 9.Has a history or current evidence of interstitial lung disease.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    IN10018 Monotherapy

    Participants will be instructed to take IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.

    Drug: IN10018

  • Experimental
    IN10018 Combination with Docetaxel

    Participants will be instructed to take IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours. Docetaxel 75mg/m2 every 21 days a cycle.

    Drug: IN10018 · Drug: Docetaxel

Interventions

  • IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.

  • Docetaxel 75mg/m2 every 21 days a cycle.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability in combination group

    Number of patients with adverse event in combination group; Number of patients with laboratory abnormalities, abnormal vital signs and abnormal 12-lead ECG in combination group

    Time frame: up to 24 months

  2. DLTs in combination group

    Number of patients with dose-limited toxicities (DLTs) in combination group

    Time frame: 21 days

  3. Phase II dose of IN10018 in combination with Docetaxel

    Determine the recommended phase II dose (RP2D) of IN10018 in combination with Docetaxel

    Time frame: up to 24 months

Secondary outcomes

  1. Safety and tolerability in IN10018 monotherapy group

    Number of patients with adverse event in monotherapy group; Number of patients with laboratory abnormalities, abnormal vital signs and abnormal 12-lead ECG in monotherapy group

    Time frame: up to 24 months

  2. DLTs in IN10018 monotherapy group

    Number of patients with dose-limited toxicities (DLTs) in monotherapy group

    Time frame: up to 24 months

  3. Objective response rate (ORR) per RECIST v1.1

    Defined as the proportion of patients with complete response (CR) or partial response (PR).

    Time frame: up to 24 months

  4. Duration of objective response (DOR) per RECIST v1.1.

    Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first

    Time frame: up to 24 months

  5. Disease Control Rate (DCR) per RECIST v1.1.

    Defined as the proportion of patients with CR, PR, or stable disease (SD)

    Time frame: up to 24 months

  6. Progression-free survival (PFS) per RECIST v1.1.

    Defined as the time from start of study treatment to first documentation of disease progression or to death due to any cause, whichever comes first.

    Time frame: up to 24 months

  7. Overall survival (OS).

    Defined as the time from the start of any study treatment to the date of death due to any cause.

    Time frame: up to 30 months

  8. Pharmacokinetics (PK):AUC

    Area under the concentration-time curve (AUC).

    Time frame: up to 24 months

  9. Pharmacokinetics (PK):Cmax

    PK: Maximum concentration (Cmax).

    Time frame: up to 24 months

  10. PK:Tmax

    Time to Cmax (Tmax).

    Time frame: up to 24 months

  11. PK:Ctrough

    Trough concentration (Ctrough).

    Time frame: up to 24 months

  12. PK:t1/2

    Elimination half-life (t1/2).

    Time frame: up to 24 months

  13. PK:CL/F

    apparent clearance (CL/F).

    Time frame: up to 24 months

  14. PK:Vd/F

    Apparent volume of distribution (Vd/F).

    Time frame: up to 24 months

07

Study locations

8 sites
  • Anyang Tumor Hospital
    Anyang, Henan, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • The Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
  • Shanghai East Hospital
    Shanghai, Shanghai, China
  • The First Affiliated Hospital of XI 'AN Jiaotong University
    Xi'an, Shanxi, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Dec 2021, 16 months.

Of 168 industry-sponsored phase 1 interventional studies under Stomach Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 65. This study's 16 months is below that.

Counting every sponsor, half of 243 studies reached it within 51 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2022
First posted
Apr 14, 2022
StartActual
Jul 9, 2020
Primary completionActual
Dec 3, 2021
CompletionActual
Mar 31, 2022
Last update
Nov 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05327231
Lead sponsor
InxMed (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Apr 14, 2022
Start date
Jul 9, 2020
Primary completion
Dec 3, 2021
Completion
Mar 31, 2022
Last update
Nov 16, 2022

Study contacts

Jin Li, Doctor
principal investigator · Shanghai East Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ifebemtinib

Start the discussion